MiniMed Prices Initial Public Offering as Medtronic Diabetes Unit Prepares to Trade Independently
MiniMed, the diabetes technology business being separated from Medtronic plc, has announced the pricing of its initial public offering (IPO) as it prepares to begin trading as an independent public company.
The company priced 28 million shares at $20 per share, raising approximately $560 million in gross proceeds. Based on the offering price, MiniMed is valued at roughly $5.6 billion.
MiniMed’s shares are expected to begin trading on the Nasdaq Global Select Market under the ticker MiniMed (NASDAQ: MMED).
Strategic Spin-Off From Medtronic
The IPO is part of Medtronic’s strategy to spin off its diabetes business, allowing the company to streamline its portfolio and focus on other core medical technology segments.
As an independent company, MiniMed will concentrate exclusively on developing and commercializing advanced diabetes management technologies, including:
- Insulin pump systems
- Continuous glucose monitoring (CGM) devices
- Automated insulin delivery platforms
The business generated approximately $2.7 billion in revenue in fiscal year 2025, reflecting renewed momentum in the diabetes technology market.
A Longstanding Leader in Diabetes Technology
MiniMed has been a pioneer in diabetes care innovation for decades. The company originally developed some of the first portable insulin pump systems before being acquired by Medtronic more than two decades ago.
Today, MiniMed continues to advance its technology portfolio with products such as the MiniMed 780G automated insulin delivery system, which integrates insulin pumps with glucose monitoring technology to help automate diabetes management.
Strong Demand for Diabetes Care Technology
The IPO comes at a time when demand for advanced diabetes management solutions is growing rapidly. Rising global diabetes rates and increased adoption of automated insulin delivery systems are driving expansion in the diabetes technology market.
As a standalone company, MiniMed will focus on expanding its product portfolio and strengthening its position within this fast-growing segment of the medical device industry.
Investor Perspective
For investors, the MiniMed IPO offers exposure to the diabetes technology and medical device sector, which continues to benefit from long-term healthcare trends and increasing adoption of digital health solutions.
Bottom Line
The successful pricing of MiniMed’s IPO marks an important milestone in Medtronic’s plan to separate its diabetes business. As MiniMed begins trading independently, the company aims to build on its legacy of innovation while pursuing new growth opportunities in the global diabetes care market.
